Ovarian Cancer

Oncology·MeSH: Ovarian Neoplasms

Prevalence

24.0 / 100K

Incidence

10.6 / 100K/yr

136 drugs in development·57 companies·134 clinical trials

Drug Pipeline by Phase

Phase 3(40)
DrugCompany
AcetaminophenMerck & Co., Inc. (MRK)
Administration of ceralasertibASTRAZENECA PLC (AZN)
Administration of ceralasertib in combination with AZD5305ASTRAZENECA PLC (AZN)
Administration of ceralasertib monotherapyASTRAZENECA PLC (AZN)
Aitua Combination AntibodyValneva SE (VALN)
avutometinibVerastem, Inc. (VSTM)
AZD5305ASTRAZENECA PLC (AZN)
cemiplimab+fianlimab fixed dose combinationREGENERON PHARMACEUTICALS, INC. (REGN)
chemotherapyZentalis Pharmaceuticals, Inc. (ZNTL)
chemotherapyIncyte Corp. (INCY)
Datopotamab DeruxtecanMerck & Co., Inc. (MRK)
Datopotamab DeruxtecanENANTA PHARMACEUTICALS INC (ENTA)
defactinibVerastem, Inc. (VSTM)
fdc fianlimab+cemiplimabREGENERON PHARMACEUTICALS, INC. (REGN)
H1 receptor antagonistMerck & Co., Inc. (MRK)
H2 receptor antagonistMerck & Co., Inc. (MRK)
incb106385Incyte Corp. (INCY)
incb123667Incyte Corp. (INCY)
incmga00012Incyte Corp. (INCY)
nemvaleukinMural Oncology plc (MURA)
niraparibGH Research PLC (GHRS)
niraparibImunon, Inc. (IMNN)
NiraparibMerck & Co., Inc. (MRK)
non-platinum chemotherapyGENELUX Corp (GNLX)
OlaparibNovartis AG (NVS)
pamiparibBeOne Medicines Ltd. (ONC)
pldGENMAB A/S (GNMSF)
pldGenmab A/S (GMAB)
regn15505+cemiplimabREGENERON PHARMACEUTICALS, INC. (REGN)
rina-sGENMAB A/S (GNMSF)
Rina-SENANTA PHARMACEUTICALS INC (ENTA)
suvemcitugApexigen, Inc. (APGN)
T- DxdASTRAZENECA PLC (AZN)
tak-853TAKEDA PHARMACEUTICAL CO LTD (TKPHF)
tak-853Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)
topotecanGenmab A/S (GMAB)
topotecanMural Oncology plc (MURA)
topotecanGENMAB A/S (GNMSF)
ToripalimabASTRAZENECA PLC (AZN)
torvutatug samrotecanASTRAZENECA PLC (AZN)
Phase 2(41)
DrugCompany
AldesleukinFilana Therapeutics Inc. (FLNA)
BA3011BioAtla, Inc. (BCAB)
BA3011ASTRAZENECA PLC (AZN)
BA3021ASTRAZENECA PLC (AZN)
BA3021BioAtla, Inc. (BCAB)
brimonidine tartrate ophthalmic solution eye dropsAbbVie Inc. (ABBV)
cyt-0851Cyteir Therapeutics, Inc. (CYT)
ENB003BioAtla, Inc. (BCAB)
ENB003ASTRAZENECA PLC (AZN)
fianlimabREGENERON PHARMACEUTICALS, INC. (REGN)
kevetrinInnovation Pharmaceuticals Inc. (IPIX)
lartesertibGH Research PLC (GHRS)
LorigerlimabMACROGENICS INC (MGNX)
lubricating eye dropsAbbVie Inc. (ABBV)
M-CENKImmunityBio, Inc. (IBRX)
Mecbotamab vedotin (BA3011)BioAtla, Inc. (BCAB)
Mirvetuximab SoravtansineAbbVie Inc. (ABBV)
navicixizumabOncoMed Pharmaceuticals Inc (OMED)
olvimulogene nanivacirepvecGENELUX Corp (GNLX)
Ozuriftamab vedotin (BA3021)BioAtla, Inc. (BCAB)
pegfilgrastimBolt Biotherapeutics, Inc. (BOLT)
PegfilgrastimSUTRO BIOPHARMA, INC. (STRO)
platinum chemotherapyGENELUX Corp (GNLX)
pldREGENERON PHARMACEUTICALS, INC. (REGN)
pldWest Pharmaceutical Services Inc. (WST)
Raludotatug DeruxtecanMerck & Co., Inc. (MRK)
sarilumabWest Pharmaceutical Services Inc. (WST)
sarilumabREGENERON PHARMACEUTICALS, INC. (REGN)
stenoparibAllarity Therapeutics, Inc. (ALLR)
stenoparib (formerly E7449)Allarity Therapeutics, Inc. (ALLR)
TopotecanSUTRO BIOPHARMA, INC. (STRO)
ToripalimabBioAtla, Inc. (BCAB)
torl-1-23Bolt Biotherapeutics, Inc. (BOLT)
trc102Tracon Pharmaceuticals, Inc. (TCON)
tuvusertibGH Research PLC (GHRS)
ubamatamabREGENERON PHARMACEUTICALS, INC. (REGN)
ubamatamabWest Pharmaceutical Services Inc. (WST)
utidelone capsule 35mg/m2/d bidBIOSTAR PHARMACEUTICALS, INC. (BSPM)
utidelone capsule 40mg/m2/d bidBIOSTAR PHARMACEUTICALS, INC. (BSPM)
utidelone capsule 50mg/m2/d bidBIOSTAR PHARMACEUTICALS, INC. (BSPM)
utidelone capsule 75mg/m2/d qdBIOSTAR PHARMACEUTICALS, INC. (BSPM)
Phase 1(29)
DrugCompany
AldesleukinENANTA PHARMACEUTICALS INC (ENTA)
AldesleukinMerus N.V. (MRUS)
cemiplimabREGENERON PHARMACEUTICALS, INC. (REGN)
CT-1119Carisma Therapeutics Inc. (CARM)
CTIM-76Context Therapeutics Inc. (CNTX)
Cytokine-Induced Memory-like Natural Killer CellsImmunityBio, Inc. (IBRX)
DT2216UNITED THERAPEUTICS Corp (UTHR)
emi-leMersana Therapeutics, Inc. (MRSN)
Interleukin 2ImmunityBio, Inc. (IBRX)
itil-306Instil Bio, Inc. (TIL)
LDE225Novartis AG (NVS)
lira-celAnixa Biosciences Inc (ANIX)
lncb74NextCure, Inc. (NXTC)
Luveltamab tazevibulinSUTRO BIOPHARMA, INC. (STRO)
men2501STEMLINE THERAPEUTICS INC (STML)
mirvetuximab + sl-172154Shattuck Labs, Inc. (STTK)
navicixizumabMereo BioPharma Group plc (MREO)
NeoVaxUNITED THERAPEUTICS Corp (UTHR)
niraparibZentalis Pharmaceuticals, Inc. (ZNTL)
NUV-1176Nuvation Bio Inc. (NUVB)
NX-1607Nurix Therapeutics, Inc. (NRIX)
NY-ESO-1 TCR/ dnTGFβRIIMerus N.V. (MRUS)
NY-ESO-1 TCR/ dnTGFβRIIENANTA PHARMACEUTICALS INC (ENTA)
NY-ESO-1 TCR/ dnTGFβRIIFilana Therapeutics Inc. (FLNA)
prolantaONCOLIX, INC. (AEPP)
RintatolimodMerus N.V. (MRUS)
RintatolimodMerck & Co., Inc. (MRK)
STRO-002SUTRO BIOPHARMA, INC. (STRO)
XmAb541Xencor Inc (XNCR)

Compare drugs

avmapki fakzynja co-pack vs MyChoice CDxavmapki fakzynja co-pack vs Acetaminophenavmapki fakzynja co-pack vs Administration of ceralasertib

Frequently asked questions

How many drugs are in development for Ovarian Cancer?

BioSniper tracks 136 drugs in development for Ovarian Cancer across 57 companies.

How many clinical trials target Ovarian Cancer?

There are 134 clinical trials targeting Ovarian Cancer tracked by BioSniper.

What is the prevalence of Ovarian Cancer?

The estimated prevalence of Ovarian Cancer is approximately 24.0 per 100,000 population.

Deep-dive into Ovarian Cancer

Full trial data, competitive analysis, and AI-powered pipeline tracking.

Start Free Analysis